Company: OFIX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-061062
Chunk: 58

Company: Orthofix Medical Inc.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 58
---
 |     | 47,664 |     | -10 |     |      — |     |     |     |     — |     |   620,585 |
|                 | 6/18/2024 |     |       — |     |       — |     |       — |     |      — |     |      — |     |       — |     |      — |     |     |     | 43,867 |     | -10 |     | 13.29 |     |   132,162 |
|                 | 6/18/2024 |     |       — |     |       — |     |       — |     |      — |     |      — |     |       — |     | 18,811 |     | -10 |     |      — |     |     |     |     — |     |   163,284 |

(1) Amounts shown represent the threshold, target and maximum amounts that could have been earned had they served for the entire fiscal year 2024 by each Named Executive Officer under our annual performance-based incentive compensation program. The actual amounts earned by each Named Executive Officer are included in the fiscal year 2024 “Non-Equity Incentive Plan Compensation” column of the Summary Compensation Table above and discussed under “—Compensation Discussion and Analysis—Elements of Executive Compensation—Cash Performance-Based Incentives – Annual Incentive Program” above. (2) Amounts shown represent the threshold and maximum amounts in shares earned based on performance if the threshold or maximum performance goals are achieved over the three-year performance period beginning on January 8, 2024. No shares were issuable for performance above the target level. (3) Amounts shown reflect the grant date fair value of equity awards, as computed in accordance with ASC 718. (4) Represents awards of time-based vesting restricted stock units and performance-based stock options granted under the Orthofix Medical Inc. 2024 CEO Inducement Plan upon Mr. Calafiore’s hire date of January 8, 2024 as President and Chief Executive Officer (subject to certain acceleration provisions, as discussed under “—Potential Payments upon Termination or Change in Control” below). (5) Represents awards of time-based vesting restricted stock units and performance-based stock options granted under the Orthofix Medical Inc. 2024 CFO Inducement Plan upon Ms. Andrew’s hire date of January 15, 2024 as Chief